MLN2704 antibody

consists of MLN591 monoclonal antibody conjugated to mantansinoid DM1; therapeutic doses of MLN2704 can be administered safely on a repetitive basis. An MTD was not defined. MLN2704 is being administered at more frequent intervals in ongoing trials to determine an optimal dosing schedule.

Also Known As:

Networked: 0 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results